Key result
Treatment with standard heart failure medications, including an SGLT2 inhibitor, resulted in clinical improvement and relief of dyspnea in a 31-year-old woman with peripartum cardiomyopathy.
Why the study?
The etiology of peripartum cardiomyopathy is multifactorial and not fully understood, motivating a review of its diagnosis and management in clinical practice.
Case Report (n=1)
No
This case report demonstrates the successful management of severe peripartum cardiomyopathy using guideline-directed medical therapy for heart failure, including the addition of an SGLT2 inhibitor.
Answers are grounded in this paper and cite their sources.
Prompt PPCM recognition remains key in peripartum dyspnea; case extends sparse literature but leaves optimal therapy open.
Introduction: Peripartum cardiomyopathy (PPCM) is generally viewed as diagnosis of exclusion in women presenting with heart failure and systolic dysfunction of unclear identifiable etiology. Etiology of PPCM is not fully understood and multifactorial. The purpose of this case is to review the diagnosis and management PPCM based on our experience in managing 31 years old woman with PPCM. Case: A 31 year old woman presented with dyspnea persisting for two days, exacerbated over the last 24 hours. She gave birth to her third child seven months ago. Patient had been experiencing dyspnea since 4 months earlier but seek no medical help. Upon physical examination, hemodynamic was stable, wet rales was noted in two thirds of the lung fields. Echocardiography revealed dilated left ventricle with eccentric hypertrophy and reduced ejection fraction (18%). Treatment was initiated with furosemide IV to resolve dyspnea, then Ramipril, bisoprolol, forxiga and spironolactone was given as heart failure therapy. Discussion: PPCM should be suspected in any peripartum women presenting with symptoms and signs of heart failure. Careful history taking and diagnostic testing especially echocardiography is important to help physicians determine the diagnosis. Conclusion: Treatment with medication adjusted for pregnancy and lactation may prevent adverse outcome, improve clinical symptoms and improve the overall cardiac functions. Long term follow up is important for patients with PPCM, since the optimal duration of medications after recovery is still unknown.
No takes yet. Share an insight, caveat, or question.
Laksono et al. (2023) conducted a case report in Peripartum Cardiomyopathy (n=1). Heart failure therapy (Furosemide, Ramipril, Bisoprolol, Dapagliflozin, Spironolactone) was evaluated on Clinical improvement. Treatment with standard heart failure medications, including an SGLT2 inhibitor, resulted in clinical improvement and relief of dyspnea in a 31-year-old woman with peripartum cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: